Medtronic presents data showing 'positive' results from MiniMed system
Medtronic announced that new data from its at-home pediatric study of the MiniMed 670G system in patients 7-13 years of age were presented at the Advanced Technologies & Treatments for Diabetes 11th International Conference in Vienna, Austria. Study results mirror data from the pivotal trial of the system in adults and adolescents, showing patients spent more Time in Range, experienced less glycemic variability, less exposure to hypoglycemia and hyperglycemia, and reduced A1C compared to baseline data using sensor-augmented pumps. The MiniMed 670G system is currently FDA approved in the U.S. for people with type 1 diabetes 14 years of age and older. Data from this study was included in an FDA application in late January to seek future expansion of the current indication to include children 7-13 years of age. Medtronic is also evaluating the system in children 2-6 years of age and will present data from this trial at a future date. However, product labeling currently warns that the system may not be safe for children under age 7 or patients using less than 8 units of insulin per day.